CN103906746B - 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 - Google Patents

用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 Download PDF

Info

Publication number
CN103906746B
CN103906746B CN201280052591.6A CN201280052591A CN103906746B CN 103906746 B CN103906746 B CN 103906746B CN 201280052591 A CN201280052591 A CN 201280052591A CN 103906746 B CN103906746 B CN 103906746B
Authority
CN
China
Prior art keywords
phenyl
compound
formula
tautomer
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280052591.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103906746A (zh
Inventor
S·K·巴加尔
M·I·肯普
D·C·米勒
Y·村田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103906746(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of CN103906746A publication Critical patent/CN103906746A/zh
Application granted granted Critical
Publication of CN103906746B publication Critical patent/CN103906746B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280052591.6A 2011-10-26 2012-10-15 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 Expired - Fee Related CN103906746B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
US61/551,628 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (2)

Publication Number Publication Date
CN103906746A CN103906746A (zh) 2014-07-02
CN103906746B true CN103906746B (zh) 2015-12-09

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280052591.6A Expired - Fee Related CN103906746B (zh) 2011-10-26 2012-10-15 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物

Country Status (28)

Country Link
US (1) US9079878B2 (enExample)
EP (1) EP2771335A2 (enExample)
JP (1) JP5946538B2 (enExample)
KR (1) KR101586966B1 (enExample)
CN (1) CN103906746B (enExample)
AP (1) AP2014007579A0 (enExample)
AU (1) AU2012328034B2 (enExample)
BR (1) BR112014009102A2 (enExample)
CA (1) CA2850925C (enExample)
CL (1) CL2014000956A1 (enExample)
CO (1) CO6940427A2 (enExample)
CR (1) CR20140185A (enExample)
CU (1) CU20140046A7 (enExample)
DO (1) DOP2014000085A (enExample)
EA (1) EA023375B1 (enExample)
EC (1) ECSP14013324A (enExample)
GT (1) GT201400079A (enExample)
IL (1) IL232267A (enExample)
MD (1) MD20140037A2 (enExample)
MX (1) MX337469B (enExample)
NI (1) NI201400031A (enExample)
PE (1) PE20141682A1 (enExample)
PH (1) PH12014500919A1 (enExample)
SG (1) SG11201401032YA (enExample)
TN (1) TN2014000147A1 (enExample)
UA (1) UA109220C2 (enExample)
WO (1) WO2013061205A2 (enExample)
ZA (1) ZA201402281B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2847858A1 (en) * 2011-09-14 2013-03-21 Dow Agrosciences Llc Methods and systems for forming boronic acids and intermediates thereof
US9163042B2 (en) 2013-12-13 2015-10-20 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
JP6779217B2 (ja) * 2014-10-24 2020-11-04 アヴェクタス リミテッド 細胞原形質膜を越える送達方法
MX2017010682A (es) 2015-02-19 2018-04-24 Purdue Pharma Lp Metodos y composiciones para disminuir el vaciado gastrico.
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
EP3397760A2 (en) 2015-12-30 2018-11-07 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CA3029132A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
AU2018271110A1 (en) 2017-05-16 2019-12-05 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CN111065383A (zh) 2017-07-11 2020-04-24 沃泰克斯药物股份有限公司 用作钠通道调节剂的羧酰胺
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
CN113272293B (zh) 2018-11-02 2024-06-14 默沙东有限责任公司 作为nav1.8抑制剂的2-胺基-n-杂芳基-烟酰胺
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
LT4069691T (lt) 2019-12-06 2024-12-10 Vertex Pharmaceuticals Incorporated Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
EP4346818B1 (en) 2021-06-04 2025-12-03 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
EP4347032A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CR20240513A (es) 2022-04-22 2025-04-30 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN119487003A (zh) 2022-04-22 2025-02-18 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083656A2 (fr) * 2001-04-10 2002-10-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur utilisation en tant qu'inhibiteurs de la mao et/ou peroxydation lipidique, leur preparation et leur application comme medicaments
US20050234118A1 (en) * 2002-07-25 2005-10-20 Dennis Bigg Novel aryllimidazole derivatives, preparation and therapeutic used thereof
CN101103112A (zh) * 2004-10-27 2008-01-09 先灵公司 抑制Nav1.8的短干扰核酸组合物和方法
US20110046129A1 (en) * 2005-12-22 2011-02-24 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
PT1747210E (pt) * 2004-05-07 2010-08-31 Warner Lambert Co Derivados de fenol e de tiofenol 3- ou 4-monossubstituídos úteis enquanto ligandos de h3
AP2780A (en) 2006-10-18 2013-09-30 Pfizer Prod Inc Biaryl ether urea compounds
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
EP2155727A1 (en) * 2007-05-03 2010-02-24 Pfizer Limited N-[6-amino-5-(phenyl)pyrazin-2-yl]-isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083656A2 (fr) * 2001-04-10 2002-10-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur utilisation en tant qu'inhibiteurs de la mao et/ou peroxydation lipidique, leur preparation et leur application comme medicaments
US20050234118A1 (en) * 2002-07-25 2005-10-20 Dennis Bigg Novel aryllimidazole derivatives, preparation and therapeutic used thereof
CN101103112A (zh) * 2004-10-27 2008-01-09 先灵公司 抑制Nav1.8的短干扰核酸组合物和方法
US20110046129A1 (en) * 2005-12-22 2011-02-24 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators

Also Published As

Publication number Publication date
JP2014530900A (ja) 2014-11-20
BR112014009102A2 (pt) 2017-04-18
MX2014004738A (es) 2014-08-01
AP2014007579A0 (en) 2014-04-30
WO2013061205A3 (en) 2013-06-27
WO2013061205A8 (en) 2014-03-27
NI201400031A (es) 2014-10-01
SG11201401032YA (en) 2014-07-30
TN2014000147A1 (fr) 2015-09-30
WO2013061205A2 (en) 2013-05-02
EA201490864A1 (ru) 2014-08-29
PH12014500919A1 (en) 2014-06-09
ECSP14013324A (es) 2014-05-31
AU2012328034B2 (en) 2015-04-23
EP2771335A2 (en) 2014-09-03
US9079878B2 (en) 2015-07-14
NZ623090A (en) 2015-10-30
KR101586966B1 (ko) 2016-01-19
CR20140185A (es) 2014-06-03
IL232267A0 (en) 2014-06-30
CL2014000956A1 (es) 2014-07-18
IL232267A (en) 2016-10-31
AU2012328034A1 (en) 2014-05-15
UA109220C2 (uk) 2015-07-27
CU20140046A7 (es) 2014-10-02
DOP2014000085A (es) 2014-08-31
MD20140037A2 (ro) 2014-08-31
HK1198650A1 (en) 2015-05-22
CN103906746A (zh) 2014-07-02
CO6940427A2 (es) 2014-05-09
KR20140069234A (ko) 2014-06-09
MX337469B (es) 2016-03-02
JP5946538B2 (ja) 2016-07-06
CA2850925A1 (en) 2013-05-02
PE20141682A1 (es) 2014-11-14
CA2850925C (en) 2017-01-10
EA023375B1 (ru) 2016-05-31
US20140296313A1 (en) 2014-10-02
ZA201402281B (en) 2015-11-25
GT201400079A (es) 2015-06-02

Similar Documents

Publication Publication Date Title
CN103906746B (zh) 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
JP6002785B2 (ja) ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
JP6067031B2 (ja) Ｎ−アミノスルホニルベンズアミド
JP6058023B2 (ja) スルホンアミド誘導体
JP5860045B2 (ja) 化合物
JP4056081B1 (ja) ピリジン誘導体
JP4657384B2 (ja) ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
JP2013532185A (ja) 化合物
JP2013532186A (ja) 化合物
JP2013536165A (ja) 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013531030A (ja) 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
JP2009514937A (ja) ピラジン誘導体
JP2009523842A (ja) ナトリウムチャネルモジュレーターとしてのピリジン誘導体
JP2009515943A (ja) アミノ酸誘導体
HK1198650B (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
OA16888A (en) (4-phenylimidazol-2-YL) ethylamine derivatives useful as sodium channel modulators
NZ623090B2 (en) (4-phenylimidazol-2-yl)ethylamine derivatives useful as sodium channel modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198650

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1198650

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151209

Termination date: 20171015

CF01 Termination of patent right due to non-payment of annual fee